Protective effects of the combination Bifidobacterium longum plus lactoferrin against NSAID-induced enteropathy

Autor: Emilia Ghelardi, Larisa Ryskalin, Erika Tirotta, Elena Piccoli, Corrado Blandizzi, Gianfranco Natale, Matteo Fornai, Rocchina Colucci, Luca Antonioli, Laura Benvenuti, Carolina Pellegrini, Daniela Gentile
Rok vydání: 2020
Předmět:
Male
0301 basic medicine
Bifidobacterium longum
Endocrinology
Diabetes and Metabolism
Pharmacology
Feces
Hemoglobins
fluids and secretions
0302 clinical medicine
Malondialdehyde
Enteropathy
Intestinal Mucosa
Nonsteroidal anti-inflammatory drugs
Intestinal damage
Lactoferrin
Bifidobacterium longum
Probiotics
Prebiotics
Bifidobacterium
Nutrition and Dietetics
biology
Lactoferrin
Chemistry
Anti-Inflammatory Agents
Non-Steroidal
Nonsteroidal anti-inflammatory drugs
NF-kappa B
food and beverages
Nonsteroidal anti-inflammatory drugs Intestinal damage Lactoferrin Bifidobacterium longum Probiotics Prebiotics
medicine.anatomical_structure
Myeloperoxidase
Signal Transduction
medicine.drug
Diclofenac
030209 endocrinology & metabolism
Ileum
Protective Agents
Intestinal damage
03 medical and health sciences
medicine
Animals
Peroxidase
030109 nutrition & dietetics
Probiotics
medicine.disease
biology.organism_classification
Toll-Like Receptor 2
Rats
Toll-Like Receptor 4
Intestinal Diseases
stomatognathic diseases
Prebiotics
biology.protein
Calprotectin
Leukocyte L1 Antigen Complex
Zdroj: Nutrition. 70:110583
ISSN: 0899-9007
Popis: Objectives Nonsteroidal anti-inflammatory drugs can exert detrimental effects in the lower digestive tract. The aim of this study was to examine the protective effects of a combination of the probiotic Bifidobacterium longum BB536 (Bifidobacterium) with the prebiotic lactoferrin in a rat model of diclofenac-induced enteropathy. Methods Enteropathy was induced in 40-wk-old male rats by intragastric diclofenac (4 mg/kg twice daily for 14 d). Lactoferrin (100 mg/kg twice daily), Bifidobacterium (2.5 × 106 CFU/rat twice daily) or their combination were administered 1 h before diclofenac. At the end of treatments, the ileum was processed for the evaluation of histologic damage, myeloperoxidase (MPO) and malondialdehyde (MDA) levels, as well as the expression of Toll-like receptors 2 and 4 (TLR-2/-4) and the activation of downstream signaling molecules (MyD88 and nuclear factor [NF]-κB p65). Blood hemoglobin and fecal calprotectin were also assessed. Results Diclofenac induced intestinal damage, along with increments of MPO and MDA, overexpression of TLR-2, TLR-4, MyD88, and NF-κB p65, increased fecal calprotectin and decreased blood hemoglobin levels. Lactoferrin or Bifidobacterium alone prevented diclofenac-induced enteric damage, and the changes in blood hemoglobin, MPO, MDA, fecal calprotectin, and NF-κB p65. Bifidobacterium, but not lactoferrin, decreased TLR-4 expression, although none of them affected MyD88 overexpression. TLR-2 expression was slightly enhanced by all treatments. The combined administration of lactoferrin and Bifidobacterium reduced further the intestinal damage, and restored MPO and blood hemoglobin levels. Conclusions Diclofenac induced ileal mucosal lesions by activation of inflammatory and pro-oxidant mechanisms. These detrimental actions were prevented by the combination of lactoferrin with Bifidobacterium likely through the modulation of TLR-2/-4/NF-κB proinflammatory pathways.
Databáze: OpenAIRE
Externí odkaz: